Pre-treatment serum albumin and mutational burden as biomarkers of response to immune checkpoint blockade. Academic Article uri icon

Overview

abstract

  • The effects of cytokine and protein stabilizing carriers, such as serum albumin, on tumor response to immune checkpoint blockade (ICB) is not well understood. By examining 1714 patients across 16 cancer types, we found that high pretreatment serum albumin level predicts favorable tumor radiographic response following ICB treatment in a dose-dependent fashion. Serum albumin is a candidate biomarker that can be combined with tumor mutational burden (TMB) for additional predictive capacity, and the tumor response rate to ICB was ~49% in the albumin-high/TMB-high group.

publication date

  • April 7, 2022

Identity

PubMed Central ID

  • PMC8990074

Digital Object Identifier (DOI)

  • 10.1038/s41698-022-00267-7

PubMed ID

  • 35393553

Additional Document Info

volume

  • 6

issue

  • 1